Oncternal Therapeutics Stock (NASDAQ: ONCT) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 9.711K |
Day Range | - - - |
52 Wk Range | 5.566 - 13.140 |
Market Cap | $26.341M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 51 |
Short Interest | 0.61% |
Days to Cover | 2.56 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Oncternal Therapeutics (NASDAQ: ONCT) through any online brokerage.
Other companies in Oncternal Therapeutics’s space includes: CERo Therapeutics Hldgs (NASDAQ:CERO), Serina Therapeutics (AMEX:SER), T2 Biosystems (NASDAQ:TTOO), Evaxion Biotech (NASDAQ:EVAX) and Lumos Pharma (NASDAQ:LUMO).
The latest price target for Oncternal Therapeutics (NASDAQ: ONCT) was reported by HC Wainwright & Co. on Monday, April 15, 2024. The analyst firm set a price target for 28.00 expecting ONCT to rise to within 12 months (a possible 214.61% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Oncternal Therapeutics (NASDAQ: ONCT) is $8.9 last updated April 18, 2024 at 9:01 AM EDT.
There are no upcoming dividends for Oncternal Therapeutics.
Oncternal Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Oncternal Therapeutics.
Oncternal Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.